DUBLIN, Feb. 22, 2024 /PRNewswire/ — The “Wilms Tumor Protein Global Market Report 2024” has been added to ResearchAndMarkets.com’s offering.
The Wilms Tumor Protein market size is expected to see strong growth in the next few years. It will grow to $4.06 billion in 2028 at a compound annual growth rate (CAGR) of 5.6%. The forecasted growth in the coming period for products related to Wilms Tumor Protein (WT1) can be attributed to trends such as personalized medicine approaches, advancements in genomic and proteomic research, initiatives for patient advocacy and support, regulatory backing for precision medicine, and the integration of biomarker testing. Additionally, major trends include a focus on early detection and screening programs, adherence to regulatory standards in diagnostic assays, increased awareness through patient advocacy initiatives, integration of next-generation sequencing (NGS), and the global expansion of diagnostic services.
The escalating incidence of kidney cancers is poised to drive the growth of the Wilms tumor protein market in the foreseeable future. Kidney cancer, characterized by abnormal cell growth within kidney tissue, can benefit from WT1 expression analysis, especially in cases where tumors are minute or challenging to biopsy. For instance, as reported by the American Cancer Society in January 2023, approximately 81,800 new cases of kidney cancer and 14,890 deaths were recorded in 2023 in the United States. Additionally, projections by Cancer Research UK suggest an estimated 21,900 new cases of kidney cancer annually in the UK by 2038-2040. Consequently, the increasing instances of kidney cancers are expected to significantly propel the growth of the Wilms tumor protein market.
The expanding demand for personalized medicine is anticipated to fuel the growth trajectory of the Wilms tumor protein (WT1) market. Personalized medicine represents an innovative healthcare approach considering individual genetic, environmental, and lifestyle variations when designing patient-specific treatment strategies. WT1 serves as a promising target antigen for cancer immunotherapy, allowing the development of tailored immunotherapy based on its protein expression and clinical correlations for cancer patients. For example, in 2022, the Food and Drug Administration (FDA) in the United States approved 12 personalized medicines, constituting approximately 34% of all newly approved therapeutic molecular entities. Hence, the increasing demand for personalized medicine stands as a significant driver propelling the growth of the Wilms tumor protein (WT1) market.
The Wilms tumor protein (WT1) market is expected to face significant constraints due to the limited understanding of tumor heterogeneity in the future. Tumor heterogeneity refers to the diverse genetic, molecular, and cellular variances present within a single type of cancer, such as Wilms tumor. This complexity poses challenges in pinpointing specific drug targets, as conventional drug development often targets specific genetic or molecular irregularities found within cancer cells. The inherent heterogeneity of Wilms tumors complicates the development of uniform treatment approaches. For instance, a study published in a prominent medical journal in 2022 delved into the genetic and molecular heterogeneity of Wilms tumors in pediatric patients. These variations can significantly impact the tumor’s aggressiveness, response to treatment, and overall prognosis. Therefore, the limited comprehension of tumor heterogeneity stands as a substantial obstacle impeding the growth of the Wilms tumor protein (WT1) market.
Key companies in the Wilms tumor protein market are directing efforts toward developing advanced detection methodologies, such as the enzyme-linked immunosorbent assay (ELISA), to offer dependable services to their market clientele. ELISA, a highly sensitive and specific method, employs specialized enzymes that bind to antibodies in the blood, detecting Host Cell Proteins (HCPs).
The Wilms tumor protein market consists of revenues earned by entities by providing services such as genetic testing and counseling, cancer diagnosis, and treatment, and pediatric oncology services. The market value includes the value of related goods sold by the service provider or included within the service offering. The wilms tumor protein market also includes sales of polymerase chain reaction (PCR) primers and probes, and research kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The main types of products related to Wilms Tumor Protein include antibodies, assay kits, recombinant proteins, and others. Antibodies, also known as immunoglobulins, are proteins produced by the immune system in response to the presence of foreign substances, such as bacteria, viruses, or other pathogens. Various detection methods, such as immunohistochemistry (IHC), enzyme-linked immunosorbent assay (ELISA), western blotting, polymerase chain reaction (PCR), and others, are applied in cancer diagnosis, cancer treatment, research and development, and other applications. End users include hospitals, diagnostic laboratories, research institutes, and others.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Key Markets Covered:
- By Product Type: Antibodies; Assay Kits; Recombinant Proteins; Other Types
- By Detection Method: Immunohistochemistry (IHC); Enzyme-Linked Immunosorbent Assay (ELISA); Western Blotting; Polymerase Chain Reaction (PCR); Other Methods
- By Application: Cancer Diagnosis; Cancer Treatment; Research and Development; Other Applications
- By End User: Hospitals; Diagnostic Laboratories; Research Institutes; Other End Users
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Companies Profiled
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Glaxosmithkline Plc
- F. Hoffmann-La Roche Ltd
- Otsuka Holdings Co Ltd
- Agilent Technologies Inc.
- Illumina Inc.
- Sumitomo Dainippon Pharma Co Ltd.
- PerkinElmer Inc.
- ZS Genetics Inc.
- Tecan Trading AG
- QIAGEN NV
- Abcam plc
- Hamilton Company
- BioLegend Inc.
- Oxford Nanopore Technologies plc
- Pacific Biosciences of California Inc.
- Sino Biological Inc.
- LI-COR Inc.
- Cell Signaling Technology Inc.
- Genetex Inc.
- Proteintech Group Inc.
- Zymo Research Corporation
- Santa Cruz Biotechnology Inc.
- Novus Biologicals LLC
- Inovio Pharmaceuticals Inc.
- OriGene Technologies Inc.
- Macrogen Inc.
- Boster Biological Technology
- Vaximm Ag
- Fitzgerald Industries International
For more information about this report visit https://www.researchandmarkets.com/r/5v0nwu
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
